Valneva stock falls after UK revokes Ixchiq vaccine approval

Valneva SE, a French specialty vaccine company, saw its shares drop on Monday after the UK Medicines and Healthcare products Regulatory Agency withdrew the marketing authorization for its Ixchiq chikungunya vaccine. The UK regulator's decision was based on a review of existing safety data, not a newly discovered safety signal. The revocation does not impact Ixchiq's licenses in the EU, Canada, Brazil, or other markets where the vaccine is currently sold.

Ixchiq was introduced in the UK in mid-2025, but Valneva had not aggressively marketed it in the country for months due to low sales among travelers. The company stated that no product is currently on the UK market, and it anticipates only a minimal financial impact from a possible recall and limited effect on overall sales revenue.

Valneva maintains that Ixchiq's benefit-risk profile is favorable when used as intended. The vaccine has been given to around 187,000 people globally, with no new safety concerns despite post-marketing evidence. The European Medicines Agency and Health Canada have also upheld Ixchiq's marketing authorization. While Valneva disagrees with the UK's decision, it chose not to challenge it due to its negligible financial and commercial effects.

The company believes the ruling aligns with its strategy of promoting Ixchiq in areas where chikungunya virus infections are most prevalent. Chikungunya is a mosquito-borne illness that can cause fever, debilitating joint and muscle pain, and other symptoms. Since its discovery in 2004, the virus has been detected in over 110 countries across Asia, Africa, Europe, and the Americas.